More on Cyclacel Pharmaceuticals earnings

|About: Cyclacel Pharmaceuticals, Inc. (CYCC)|By:, SA News Editor

Cyclacel Pharmaceuticals (CYCC) Q2 slips on a per share basis as losses come in higher than anticipated.

Q2 EPS of ($0.10), versus ($0.45) reported last year.

Total revenue of $264K compared to $26K in prior year.

R&D expenses were $2.6M compared to $1.7M for the same period in 2012, primarily due to clinical trial and manufacturing costs.

Cash and cash equivalents totaled $33.7M.

Shares -4.4% AH.